Picture loading failed.

Pre-Made Ustekinumab biosimilar, Whole mAb, Anti-IL12B Antibody: Anti-CLMF/CLMF2/IL-12B/IMD28/IMD29/NKSF/NKSF2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ustekinumab, sold under the brand name Stelara®, is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis, targeting both IL-12 and IL-23.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-605-1mg 1mg 3090
GMP-Bios-ab-605-10mg 10mg Inquiry
GMP-Bios-ab-605-100mg 100mg Inquiry
GMP-Bios-ab-605-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Ustekinumab biosimilar, Whole mAb, Anti-IL12B Antibody: Anti-CLMF/CLMF2/IL-12B/IMD28/IMD29/NKSF/NKSF2 therapeutic antibody
INN Name Ustekinumab
TargetIL12B
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure3hmw:HL/3hmx:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2008
Year Recommended2009
CompaniesCentocor Inc;Janssen Biotech;Medarex
Conditions ApprovedCrohn's disease;Plaque psoriasis;Psoriatic arthritis
Conditions ActiveUlcerative colitis;Spondylarthritis;Systemic lupus erythematosus;Atopic dermatitis
Conditions DiscontinuedMultiple sclerosis;Palmoplantar pustulosis;Primary biliary cirrhosis;Rheumatoid arthritis;Sarcoidosis
Development TechMedarex UltiMAb Mouse